PAHO | Bigg Rec

Results: 1 - 10 of 3,682

Total: 3,682 recommendations

HIV and infant feeding. Offer enhanced community- and facility-based interventions to support mothers living with HIV who are breastfeeding in order to optimize ART adherence, improve retention of mother-and-infant pairs in care and optimize breastfeeding

Year: 2025

Institution: World Health Organization

Recommended in favor

Conditional

Certainty of evidence

Very low

Use of tenofovir and abacavir for initial and subsequent regimens in HIV treatment. Abacavir (ABC) or tenofovir alafenamide (TAF) + lamivudine (3TC) or emtricitabine (FTC) is the suggested nucleoside reverse transcriptase inhibitor (NRTI) backbone for subsequent ART in children < 30 kg. This includes children previously treated with ABC or zidovudine (AZT)

Year: 2025

Institution: World Health Organization

Recommended in favor

Conditional

Use of tenofovir and abacavir for initial and subsequent regimens in HIV treatment. Tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) + lamivudine (3TC) or emtricitabine (FTC) is the preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone for initial and subsequent ART in adults, adolescents and children > 30 kg. This includes individuals previously treated with or exposed to tenofovir or zidovudine (AZT).

Year: 2025

Institution: World Health Organization

Recommended in favor

Strong

Certainty of evidence

Moderate

HIV and infant feeding. In settings where the national programme recommends replacement feeding: mothers living with HIV who are receiving ART and virally suppressed should be offered the choice of breastfeeding and supported in their infant feeding choice.

Year: 2025

Institution: World Health Organization

Recommended in favor

Strong

Certainty of evidence

Low

In adults and adolescents with HIV eligible for tuberculosis preventive treatment (TPT), three months of weekly isoniazid + rifapentine (3HP) is the suggested preferred regimen; six or nine months of daily isoniazid (6H or 9H) are alternative regimens.

Year: 2025

Institution: World Health Organization

Recommended in favor

Conditional

Certainty of evidence

Low

Use of darunavir/ritonavir and other protease inhibitors in HIV treatment. Darunavir/ritonavir (DRV/r) is the preferred boosted protease inhibitor option for antiretroviral treatment.

Year: 2025

Institution: World Health Organization

Recommended in favor

Strong

Certainty of evidence

Moderate

Use of darunavir/ritonavir and other protease inhibitors in HIV treatment. Atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r) can be used as an alternative boosted protease inhibitor for antiretroviral treatment

Year: 2025

Institution: World Health Organization

Recommended in favor

Conditional

Certainty of evidence

Moderate

Infant postnatal prophylaxis. Infants who are at high risk of acquiring HIV should receive a three-drug regimen, with ABC/3TC-DTG as the preferred option.

Year: 2025

Institution: World Health Organization

Recommended in favor

Strong

Certainty of evidence

Low

Infant postnatal prophylaxis.Breastfeeding infants who complete six weeks of a three-drug regimen should follow with single-drug prophylaxis until maternal viral suppression is achieved or for the remainder of breastfeeding. NVP is the preferred option

Year: 2025

Institution: World Health Organization

Recommended in favor

Strong

Certainty of evidence

Moderate

Infant postnatal prophylaxis.Breastfeeding infants who complete six weeks of a three-drug regimen should follow with single-drug prophylaxis until maternal viral suppression is achieved or for the remainder of breastfeeding. DTG is an alternative option

Year: 2025

Institution: World Health Organization

Recommended in favor

Conditional

Certainty of evidence

Very low